Features of bile acid metabolism in patients with cholelithiasis
https://doi.org/10.31146/1682-8658-ecg-198-2-54-63
Abstract
Despite the success of medicine, the problem of cholelithiasis does not lose its relevance, the prevalence of the disease is constantly growing, it’s “rejuvenation” is observed. The leading place in the pathogenesis of cholelithiasis is occupied by an excess of cholesterol in the bile, a lack of bile acids and a change in their ratio. This article discusses the role of bile acids in individual parts of the metabolism and the features of bile acid metabolism in cholelithiasis. The article also presents the results of an original study, during which the levels of bile acids in the blood plasma and in the cystic bile of patients with cholelithiasis were determined by chromatography-mass spectrometry.
About the Authors
Yu. A. Fominykh
Saint-Petersburg State Pediatric Medical University; Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
K. N. Nadzhafova
Saint-Petersburg State Pediatric Medical University
Russian Federation
Russian Federation
G. G. Rodionov
The Nikiforov Russian Center of Emergency and Radiation Medicine, EMERCOM of Russia
Russian Federation
Russian Federation
I. I. Shantyr
The Nikiforov Russian Center of Emergency and Radiation Medicine, EMERCOM of Russia
Russian Federation
Russian Federation
E. V. Svetkina
The Nikiforov Russian Center of Emergency and Radiation Medicine, EMERCOM of Russia
Russian Federation
Russian Federation
I. A. Gorbacheva
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
References
1. Uspensky Yu.P., Fominykh Yu.A., Nadzhafova K. N., Kosheev A. V., Kosareva D. M., Nikitina D. E. Using an ursodeoxycholic acid with mebeverine in patients with cholelithiasis after cholecystectomy. Doctor. 2021;9:27-33. (in Russ.) doi: 10.29296/25877305-2021-09-05@@ Успенский Ю. П., Фоминых Ю. А., Наджафова К. Н., Кощеев А. В., Косарева Д. М., Никитина Д. Е. Опыт применения комбинированной схемы с препаратами урсодезоксихолевой кислоты и мебеверина у пациентов с желчнокаменной болезнью, перенесших холецистэктомию. Врач. 2021;9:27-33.
2. UspenskyYu.P., FominykhYu.A., Nadzhafova K. N., et al. Pathogenetic aspects of the development of cholelithiasis in patients with metabolic syndrome. Terapevticheskii arkhiv. 2021; 93(2): 209-214. (in Russ.) doi: 10.26442/00403660.2021.02.200616@@ Успенский Ю. П., Фоминых Ю. А., Наджафова К. Н. и др. Патогенетические аспекты развития желчнокаменной болезни у больных с метаболическим синдромом. Терапевтический архив. 2021; 93(2): 209-214.
3. Ilchenko A. A. [Bile acids in normal and pathological conditions]. Eksp Klin Gastroenterol. 2010;(4):3-13. (in Russ.)@@ Ильченко А. А. Желчные кислоты в норме и при патологии. Экспериментальная и клиническая гастроэнтерология. 2010; 4:3-13.
4. Makarova K.S., Sayfutdinov R. G. The role of bile acids in diseases of the biliary system. Siberian Medical Journal. 2013;1:27-29. (in Russ.)@@ Макарова К. С., Сайфутдинов Р. Г. Роль желчных кислот при заболеваниях билиарной системы. Сибирский медицинский журнал. 2013;1:27-29.
5. Zagoskin P.P., Erlykina E. I. Bile acids are a new type of steroid hormones regulating nonspecific energy expenditure of the body. Modern technologies in medicine. 2020;12(5):114-128. (in Russ.) doi:10.17691/stm2020.12.5.13@@ Загоскин П. П., Ерлыкина Е. И. Желчные кислоты - новый тип стероидных гормонов, регулирующих неспецифические энерготраты организма. Современные технологии в медицине. 2020;12(5):114-128. doi:10.17691/stm2020.12.5.13
6. Ramirez-Perez O., Cruz-Ramon V., Chinchilla-Lopez P., Mendez-Sanchez N. The role of the gut microbiota in bile acid metabolism. Ann Hepatol 2017; 16(Suppl 1): 15-20. doi: 10.5604/01.3001.0010.5494
7. Allegretti J.R., Kearney S., Li N., Bogart E., et al. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther. 2016; 43(11): 1142-1153. doi: 10.1111/apt.13616
8. Watanabe M., Fukiya S., Yokota A.Comprehensive evaluation of the bactericidal activities of free bile acids in the large intestine of humans and rodents. J LipidRes. 2017; 58(6):1143-1152. doi: 10.1194/jlr.M075143
9. Kliewer S.A., Mangelsdorf D. J. Bile acids as hormones: the FXR-FGF15/19 pathway. DigDis. 2015; 33(3): 327-331. doi:10.1159/000371670
10. Ding L., Yang L., Wang Z., Huang W. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B. 2015; 5(2): 135-144. doi:10.1016/j.apsb.2015.01.004
11. De MagalhaesFilho C.D., Downes M., Evans R. M. Farnesoid X receptor an emerging target to combat obesity. DigDis. 2017; 35(3): 185-190. doi:10.1159/000450909
12. Xia Y., Zhang F., Zhao S., et al. Adiponectin determines farnesoid X receptor agonism-mediated cardioprotection against post-infarction remodelling and dysfunction. Cardiovasc Res. 2018;114(10):1335-1349. doi:10.1093/cvr/cvy093
13. Jin L., Wang R., Zhu Y., et al. Selective targeting of nuclear receptor FXR byavermectin analogues with therapeutic effects on nonalcoholicfatty liver disease. Sci Rep 2015; 5: 17288. doi: 10.1038/srep17288
14. Ding L., Yang L., Wang Z., Huang W. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B. 2015; 5(2): 135-144. doi: 10.1016/j.apsb.2015.01.004
15. Chavez-Talavera O., Tailleux A., Lefebvre P., Staels B. Bile acid control of metabolism and inflammation in obesity, type 2 diabetes, dyslipidemia, and nonalcoholic fatty liverdisease. Gastroenterol. 2017; 152(7): 1679-1694.e3. doi: 10.1053/j.gastro.2017.01.055
16. Takeda S., Kadowaki S., Haga T., et al. Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett. 2002; 520(1-3): 97-101. doi: 10.1016/s0014-5793(02)02775-8
17. Keitel V., Stindt J., Häussinger D. Bile acid-activated receptors: GPBAR1 (TGR5) and other g protein-coupled receptors. Handb Exp Pharmacol 2019; 256: 19-49. doi: 10.1007/164_2019_230
18. Svensson P. A., Olsson M., Andersson-Assarsson J.C., et al. The TGR5 gene is expressed in human subcutaneous adipose tissue and is associated with obesity, weight loss and resting metabolic rate. Biochem Biophys Res Commun. 2013; 433(4): 563-566. doi: 10.1016/j.bbrc.2013.03.031
19. Carazo A., Hyrsova L., Dusek J., et al. Acetylated deoxycholic (DCA) and cholic (CA) acids are potent ligands of pregnane X (PXR) receptor. Toxicol Lett. 2017; 265: 86-96.doi: 10.1016/j.toxlet.2016.11.013
20. Ali A. H., Carey E. J., Lindor K. D. Recent advances in the development of farnesoid X receptor agonists. Ann Transl Med. 2015;3(1):5.doi: 10.3978/j.issn.2305-5839.2014.12.06
21. Li Z., Lin B., Lin G., et al. Circulating FGF19 closely correlates with bile acid synthesis and cholestasis in patients with primary biliary cirrhosis. PLoS One. 2017; 12(6): e0178580, doi: 10.1371/journal.pone.0178580
22. Usai Satta P., Oppia F., Cabras F. Overview of pathophysiological features of GERD. Minerva Gastroenterol Dietol. 2017; 63(3): 184-197.
23. Ikeda Y., Morita S. Y., Terada T. Cholesterol attenuates cytoprotective effects of phosphatidylcholine against bile salts. Sci Rep. 2017; 7(1): 306.doi: 10.1038/s41598-017-00476-2
24. Mostarda S., Passeri D., Carotti A., et al. Synthesis, physicochemical properties, and biological activity of bile acids 3-glucuronides: novel insights into bile acid signalling and detoxification. Eur J Med Chem. 2018; 144: 349-358.doi: 10.1016/j.ejmech.2017.12.034
25. Schmid A., Neumann H., Karrasch T., et al. Bile acid metabolome after an oral lipid tolerance test by liquid chromatography-tandem mass spectrometry (LC-MS/MS). PLoS One. 2016; 11(2): e0148869.doi: 10.1371/journal.pone.0148869
26. Deutschmann K., Reich M., Klindt C., et al. Bile acid receptors in the biliary tree: TGR5 in physiology and disease. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(4 Pt B): 1319-1325, doi: 10.1016/j.bbadis.2017.08.021
27. Li T., Chiang J. Y. Bile acid signaling in metabolic disease and drug therapy. Pharmacol Rev. 2014; 66(4): 948-983.doi: 10.1124/pr.113.008201
28. Minnullina Z. S., Kiyashko S. V., Makarova K. S., et al. The content of bile acids in the blood serum of healthy people. Practical medicine. 2015; 6(91): 119-121. (in Russ.)@@ Миннуллина З. Щ., Кияшко С. В., Макарова К. С. и др. Содержание желчных кислот в сыворотке крови здоровых людей. Практическая медицина. 2015; 6(91): 119-121.
29. Burka A.A., Neborachko V. S. Determination of the content of bile acids in the blood serum of patients with acute cholecystitis. Clinical surgery. 1977;12:18-21. (in Russ.)@@ Бурка А. А., Неборачко В. С. Определение содержания желчных кислот в сыворотке крови больных острым холециститом. Клиническая хирургия. 1977;12:18-21.
30. Ilchenko A. A., Morozov I. A., Khomeriki S. G., et al. Cholesterosis of the gallbladder. Moscow. GEOTAR-Media Publ., 2007. (in Russ.)@@ Ильченко А. А., Морозов И. А., Хомерики С. Г. идр. Холестероз желчного пузыря. М.: ГЭОТАР-Медиа; 2007.
31. Bystrovskaya E. V., Ilchenko A. A., Silvestrova S. Yu. [Biochemical characteristics of operating bile composition in different types of cholecystolithiasis]. Eksp Klin Gastroenterol. 2010;(6):3-6. (in Russ.)@@ Быстровская Е. В., Ильченко А. А., Сильвестрова С. Ю. Особенности биохимического состава операционной желчи при различных видах холецистолитиаза. Экспериментальная и клиническая гастроэнтерология. 2010; 6:3-6.
32. KarbachYa.I., Slivka O. Ya., Fishchenko A. Ya. Bile acids in patients with calculous cholecystitis. Clinical medicine. 1973;51(12):61-65. (in Russ.)@@ Карбач Я. И., Сливка О. Я., Фищенко А. Я. Желчные кислоты у больных калькулёзным холециститом. Клиническая медицина. 1973;51(12):61-65.
33. Tonkih Yu., Tsukanov V. Spectrum of bile acids of bile and serum lipids in cholelithiasis in the indigenous and alien population of Evenkia. Doctor. 2014;1:72-74. (in Russ.)@@ Тонких Ю., Цуканов В. Cпектр желчных кислот желчи и липидов сыворотки крови при холелитиазе у коренного и пришлого населения Эвенкии. Врач. 2014;1:72-74.
34. Klimenko V. N., Sivolap D. V., Kaplaushenko A. G., Varinsky B. A. Bile acid profile in patients operated for cholelithiasis (cholecystectomy), according to liquid chromatography with mass spectrometric detection. Zaporozhye Medical Journal. 2017;19(6):752-757. (in Russ.) doi: 10.14739/2310-1210.2017.6.114710@@ Клименко В. Н., Сиволап Д. В., Каплаушенко А. Г., Варинский Б. А. Профиль желчных кислот у больных, оперированных по поводу желчнокаменной болезни (холецистэктомия), по данным жидкостной хроматографии с масс-спектрометрической детекцией. Запорожский медицинский журнал. 2017;19(6):752-757. doi: 10.14739/2310-1210.2017.6.114710
35. Vakhrushev Ya.M., Lukashevich A. P., Penkina I. A., Suchkova E. V.Comparative analysis of the spectrum of bile acids in non-alcoholic fatty liver disease and cholelithiasis. Therapeutic Archive. 2019;91(2):48-51. (in Russ.) doi: 10.26442/00403660.2019.02.000105@@ Вахрушев Я. М., Лукашевич А. П., Пенкина И. А., Сучкова Е. В. Сравнительный анализ спектра желчных кислот при неалкогольной жировой болезни печени и желчнокаменной болезни. Терапевтический архив. 2019; 91(2): 48-51. doi: 10.26442/00403660.2019.02.000105
36. Perwaiz S., Tuchweber B., Mignault D., et al. Determination of bile acids in biological fluids by liquid chromatography-electrospray tandem mass spectrometry. J Lipid Res. 2001;42(1):114-9.
Review
For citations:
Fominykh Yu.A., Nadzhafova K.N., Rodionov G.G., Shantyr I.I., Svetkina E.V., Gorbacheva I.A. Features of bile acid metabolism in patients with cholelithiasis. Experimental and Clinical Gastroenterology. 2022;(2):54-63. (In Russ.) https://doi.org/10.31146/1682-8658-ecg-198-2-54-63
Views:
350
Email this article 